Research graph
References from Virtual screening of Kv1.3 inhibitors and investigation of their molecular mechanisms in alleviating alcoholic liver injury in mice. Local targets link to admitted publications; unresolved targets remain external evidence.
Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016
10.1016/s0140-6736(18)31310-2 · 2018 · External reference
Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: a systematic review and meta-analysis
10.1111/liv.15312 · 2022 · External reference
Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study
10.1016/s2468-2667(20)30062-1 · 2020 · External reference
Alcohol-associated Liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic
10.1016/j.cgh.2022.03.017 · 2022 · External reference
Alcoholic liver disease: pathogenesis and new targets for therapy
10.1038/nrgastro.2011.134 · 2011 · External reference
Effect of ethanol on lipid metabolism
10.1016/j.jhep.2018.10.037 · 2019 · External reference
Gut-liver axis in alcoholic liver disease
10.1053/j.gastro.2014.10.042 · 2015 · External reference
Inflammatory pathways in alcoholic steatohepatitis
10.1016/j.jhep.2018.10.023 · 2019 · External reference
Blockage of Kv1.3 regulates macrophage migration in acute liver injury by targeting δ-catenin through RhoA signaling
10.7150/ijbs.38950 · 2020 · External reference
Review on biological characteristics of Kv1.3 and its role in liver diseases
2021 · External reference
Ion channels in innate and adaptive immunity
10.1146/annurev-immunol-032414-112212 · 2015 · External reference
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?
10.1038/307465a0 · 1984 · External reference
Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators
10.1038/s41467-022-31285-5 · 2022 · External reference
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance
10.1073/pnas.1221206110 · 2013 · External reference
Liver macrophages in health and disease
10.1016/j.immuni.2022.08.002 · 2022 · External reference
Kv1.3 knockdown attenuates alcohol-related liver injury in mice through induction of tryptamine
10.1038/s41401-025-01544-4 · 2025 · External reference
ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide
10.1074/jbc.273.49.32697 · 1998 · External reference
Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels
10.1016/s0021-9258(17)46707-x · 1993 · External reference
Discovery of K(V) 1.3 ion channel inhibitors: medicinal chemistry approaches and challenges
10.1002/med.21800 · 2021 · External reference
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases
10.1016/j.toxicon.2011.07.016 · 2012 · External reference
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial
10.1371/journal.pone.0180762 · 2017 · External reference
Voltage-gated potassium channel 1.3: a promising molecular target in multiple disease therapy
10.1016/j.biopha.2024.116651 · 2024 · External reference
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators
10.1124/mol.65.6.1364 · 2004 · External reference
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases
10.1124/mol.105.015669 · 2005 · External reference
Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug
10.1073/pnas.2113536119 · 2022 · External reference
Mouse model of chronic and binge ethanol feeding (the NIAAA model)
10.1038/nprot.2013.032 · 2013 · External reference
Alcoholic liver disease
10.1038/s41572-018-0014-7 · 2018 · External reference
Prednisolone or pentoxifylline for alcoholic hepatitis
10.1056/nejmoa1412278 · 2015 · External reference
ACG clinical guideline: alcoholic liver disease
10.1038/ajg.2017.469 · 2018 · External reference
Alcohol's effect on host defense
10.35946/arcr.v37.2.01 · 2015 · External reference
BmKK2, a thermostable Kv1.3 blocker from Buthus martensii karsch (BmK) scorpion, inhibits the activation of macrophages via Kv1.3-NF-κB- NLRP3 axis
10.1016/j.jep.2023.116624 · 2023 · External reference
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease
10.1124/jpet.112.191890 · 2012 · External reference
Voltage-gated potassium channel Kv1.3 as a target in therapy of cancer
10.3389/fonc.2019.00933 · 2019 · External reference
Plantanone C attenuates LPS-stimulated inflammation by inhibiting NF-κB/iNOS/COX-2/MAPKs/Akt pathways in RAW 264.7 macrophages
10.1016/j.biopha.2021.112104 · 2021 · External reference
Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS
10.1016/j.biopha.2022.113532 · 2022 · External reference
Novel tryptanthrin derivatives with benzenesulfonamide substituents: design, synthesis, and anti-inflammatory evaluation
10.1016/j.ejmech.2022.114956 · 2023 · External reference
Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages
10.1074/jbc.m605617200 · 2006 · External reference
Endogenous voltage-gated potassium channels in human embryonic kidney (HEK293) cells
10.1002/(sici)1097-4547(19980601)52:5<612::aid-jnr13>3.0.co;2-3 · 1998 · External reference
Endogenous voltage-gated potassium channels in human embryonic kidney (HEK293) cells
10.1002/(sici)1097-4547(19980601)52:5<612::aid-jnr13>3.0.co;2-3 · ExternalCitation · doi-reference
Discovery of K(V) 1.3 ion channel inhibitors: medicinal chemistry approaches and challenges
10.1002/med.21800 · ExternalCitation · doi-reference
Plantanone C attenuates LPS-stimulated inflammation by inhibiting NF-κB/iNOS/COX-2/MAPKs/Akt pathways in RAW 264.7 macrophages
10.1016/j.biopha.2021.112104 · ExternalCitation · doi-reference
Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS
10.1016/j.biopha.2022.113532 · ExternalCitation · doi-reference
Voltage-gated potassium channel 1.3: a promising molecular target in multiple disease therapy
10.1016/j.biopha.2024.116651 · ExternalCitation · doi-reference
Alcohol-associated Liver disease mortality increased from 2017 to 2020 and accelerated during the COVID-19 pandemic
10.1016/j.cgh.2022.03.017 · ExternalCitation · doi-reference
Novel tryptanthrin derivatives with benzenesulfonamide substituents: design, synthesis, and anti-inflammatory evaluation
10.1016/j.ejmech.2022.114956 · ExternalCitation · doi-reference
Liver macrophages in health and disease
10.1016/j.immuni.2022.08.002 · ExternalCitation · doi-reference
BmKK2, a thermostable Kv1.3 blocker from Buthus martensii karsch (BmK) scorpion, inhibits the activation of macrophages via Kv1.3-NF-κB- NLRP3 axis
10.1016/j.jep.2023.116624 · ExternalCitation · doi-reference
Inflammatory pathways in alcoholic steatohepatitis
10.1016/j.jhep.2018.10.023 · ExternalCitation · doi-reference
Effect of ethanol on lipid metabolism
10.1016/j.jhep.2018.10.037 · ExternalCitation · doi-reference
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases
10.1016/j.toxicon.2011.07.016 · ExternalCitation · doi-reference
Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels
10.1016/s0021-9258(17)46707-x · ExternalCitation · doi-reference
Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016
10.1016/s0140-6736(18)31310-2 · ExternalCitation · doi-reference
Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study
10.1016/s2468-2667(20)30062-1 · ExternalCitation · doi-reference
Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?
10.1038/307465a0 · ExternalCitation · doi-reference
ACG clinical guideline: alcoholic liver disease
10.1038/ajg.2017.469 · ExternalCitation · doi-reference
Mouse model of chronic and binge ethanol feeding (the NIAAA model)
10.1038/nprot.2013.032 · ExternalCitation · doi-reference
Alcoholic liver disease: pathogenesis and new targets for therapy
10.1038/nrgastro.2011.134 · ExternalCitation · doi-reference
Kv1.3 knockdown attenuates alcohol-related liver injury in mice through induction of tryptamine
10.1038/s41401-025-01544-4 · ExternalCitation · doi-reference
Structures of the T cell potassium channel Kv1.3 with immunoglobulin modulators
10.1038/s41467-022-31285-5 · ExternalCitation · doi-reference
Alcoholic liver disease
10.1038/s41572-018-0014-7 · ExternalCitation · doi-reference
Gut-liver axis in alcoholic liver disease
10.1053/j.gastro.2014.10.042 · ExternalCitation · doi-reference
Prednisolone or pentoxifylline for alcoholic hepatitis
10.1056/nejmoa1412278 · ExternalCitation · doi-reference
Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance
10.1073/pnas.1221206110 · ExternalCitation · doi-reference
Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug
10.1073/pnas.2113536119 · ExternalCitation · doi-reference
ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide
10.1074/jbc.273.49.32697 · ExternalCitation · doi-reference
Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent K+ channel in macrophages
10.1074/jbc.m605617200 · ExternalCitation · doi-reference
Epidemic characteristics of alcohol-related liver disease in Asia from 2000 to 2020: a systematic review and meta-analysis
10.1111/liv.15312 · ExternalCitation · doi-reference
Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease
10.1124/jpet.112.191890 · ExternalCitation · doi-reference
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases
10.1124/mol.105.015669 · ExternalCitation · doi-reference
Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators
10.1124/mol.65.6.1364 · ExternalCitation · doi-reference
Ion channels in innate and adaptive immunity
10.1146/annurev-immunol-032414-112212 · ExternalCitation · doi-reference
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial
10.1371/journal.pone.0180762 · ExternalCitation · doi-reference
Voltage-gated potassium channel Kv1.3 as a target in therapy of cancer
10.3389/fonc.2019.00933 · ExternalCitation · doi-reference
Alcohol's effect on host defense
10.35946/arcr.v37.2.01 · ExternalCitation · doi-reference
Blockage of Kv1.3 regulates macrophage migration in acute liver injury by targeting δ-catenin through RhoA signaling
10.7150/ijbs.38950 · ExternalCitation · doi-reference
